大規模な国際共同治験により、合併症のない心筋梗塞を起こしたものの心機能が正常に保たれている患者に対し、ベータ遮断薬による治療は有効ではないことが明らかになった。REBOOT試験の結果は、数十年にわたる標準的な医療慣行に疑問を投げかけるものである。また、同試験では女性患者において、薬を服用した場合のリスクが高まることが示された。
REBOOT試験は、スペインとイタリアの109の病院で8505人の患者を対象に実施された。参加者は退院後、標準的な最新のケアを受けた上で、ベータ遮断薬を服用するグループと服用しないグループに無作為に割り当てられた。研究チームが中央値で約4年間追跡調査を行った結果、心機能が保たれている患者において、死亡率や心筋梗塞の再発、心不全による入院の有意な減少は認められなかった。
AIによるレポート AIによって生成された画像 事実確認済み
New data presented at the European Renal Association’s 63rd Congress in Glasgow and published in three major medical journals found that finerenone slowed kidney-function decline in adults with chronic kidney disease (CKD) without diabetes and reduced the risk of a combined kidney-and-cardiovascular outcome. A separate pooled analysis that combined results across finerenone studies also reported fewer kidney and heart-failure events in a broader CKD population.
A major Cochrane review of 17 clinical trials involving over 20,000 participants has concluded that drugs targeting amyloid beta in the brain provide no meaningful benefits for patients with mild cognitive impairment or early Alzheimer’s. These treatments also raise the risk of brain swelling and bleeding. Researchers urge a shift to alternative pathways for future treatments.
AIによるレポート 事実確認済み
A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.
A large U.S. study has found that 27 percent of patients with resistant hypertension have hypercortisolism, an excess of the stress hormone cortisol. The MOMENTUM study, involving 1,086 participants across 50 centers, showed this condition is far more common than previously thought in those whose blood pressure remains high despite multiple medications. The discovery suggests screening for elevated cortisol could help explain treatment failures.
AIによるレポート
A new study shows that slowing breathing rates can reduce anxiety-like behaviors even without any conscious effort or belief in its effects. Researchers used mice to demonstrate that the benefits come from physiological changes rather than placebo. The findings were presented at a summit in Los Angeles earlier this month.